Kawai Yukinori, Fujii Yoshimine, Akimoto Katsuya, Takahashi Masayuki
Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawaku, Tokyo, Japan.
Chem Pharm Bull (Tokyo). 2010 Aug;58(8):1051-6. doi: 10.1248/cpb.58.1051.
The establishment of a new index for the profile of serum protein binding was analyzed theoretically. The in vitro pharmacological activity ratio of the inhibition constant in the absence of serum protein to that in its presence (activity ratio), which represents the extent of specific binding to serum protein, was suggested as the new index. To clarify the usefulness of the activity ratio, theoretical analysis by the activity ratio for 3% human serum albumin was examined in comparison with conventional methods of equilibrium dialysis. In-house very late antigen-4 antagonists were used as model compounds, whose pharmacokinetics were strongly influenced by serum protein binding. Although the theoretical and actual unbound fractions were similar, the latter tended to be slightly lower than the former. This small difference was considered to correspond to nonspecific binding. These results suggested that the specific and nonspecific binding could be discriminated by comparing the activity ratio data with those of conventional methods. Moreover, the activity ratio was suggested to be useful in profiling the influence of protein binding on pharmacokinetics. In conclusion, it was considered that the activity ratio could avoid the risk of misleading interpretation by nonspecific binding in pharmacokinetics/pharmacological activity. Moreover, the activity ratio was considered to be valuable as one of the useful parameters in pharmacokinetics profiling and as a tool of rational drug design for drug discovery.
从理论上分析了血清蛋白结合谱新指标的建立。提出将无血清蛋白时的抑制常数与有血清蛋白时的抑制常数的体外药理活性比(活性比)作为新指标,该活性比代表了与血清蛋白特异性结合的程度。为阐明活性比的实用性,将其对3%人血清白蛋白的理论分析与传统平衡透析方法进行了比较。使用内部晚期抗原-4拮抗剂作为模型化合物,其药代动力学受血清蛋白结合的强烈影响。虽然理论和实际未结合分数相似,但后者往往略低于前者。这种小差异被认为对应于非特异性结合。这些结果表明,通过将活性比数据与传统方法的数据进行比较,可以区分特异性和非特异性结合。此外,活性比被认为有助于分析蛋白结合对药代动力学的影响。总之,认为活性比可以避免药代动力学/药理活性中非特异性结合导致的误导性解释风险。此外,活性比被认为是药代动力学分析中有用的参数之一,也是药物发现中合理药物设计的工具。